Navigation Links
Novartis marks World CML Day with update on global research program to evaluate whether Ph+ CML patients can live treatment-free
Date:9/19/2013

tinues," "commitment," "providing support," or similar expressions, or by express or implied discussions regarding potential new indications or labeling for Novartis Ph+ CML products or regarding potential future revenues from such products. You should not place undue reliance on these statements.  Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with a Novartis Ph+ CML product to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any Novartis Ph+ CML product will be approved for any additional indications or labeling in any market. Nor can there be any guarantee that any Novartis Ph+ CML product will achieve any particular levels of revenue in the future. In particular, management's expectations regarding such products could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; unexpected clinical trial results, including unexpected new clinical data and unexpected additional analysis of existing clinical data; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; unexpected manufacturing issues; the impact that the foregoing factors could have on the values attributed to the Novartis Group's assets and liabilities as recorded in the Group's consolidated balance sheet, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the infor
'/>"/>
SOURCE Novartis
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Global Lung Cancer Therapeutics Market 2013 Report Featuring Leading Players Such As AstraZeneca, Bristol-Myers Squibb, Eli Lilly and Co., GlaxoSmithKline, Hoffmann-La Roche, Novartis And Others
2. Novartis highlights new findings in advancing care for patients with 170 abstracts in breast, lung and blood cancers at ASCO and EHA
3. Leaders from Pfizer, Novartis and J&J Challenge Industry to Disrupt R&D
4. Novartis launches the Cancer Cell Line Encyclopedia to catalog worlds cancer cell lines
5. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
6. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
7. Spanish researchers writing in cell describe the 9 hallmarks of aging
8. Discovery of gene mutation causing Sturge-Weber syndrome, port-wine stain birthmarks offers new hope
9. Nutra Pharma Patent and Trademarks Published in India
10. Spider Bully for Less: My Cleaning Products Marks Down the Spray for its Christmas Special
11. My Cleaning Products Marks Down Its Bed Bug Bully Price by 20%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... Cambridge, MA (PRWEB) April 28, 2015 ... Safety (ACRES), a Massachusetts-based multi-stakeholder, non-profit organization dedicated ... creation of a shared global system for clinical ... SYNERGY , an innovative new type of clinical ... “The future of clinical research is changing,” said ...
(Date:4/27/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the year ended December 31, 2014. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... did not provide the outcome management and investors ... at iCo Therapeutics", said Andrew Rae , ...
(Date:4/27/2015)... 27, 2015 Dr. Robert Hanzlik, whose ... toxicity carries implications for advancing the creation of safer ... National University , the second-largest private, nonprofit university ... Hanzlik, a professor at the University of Kansas School ... design, starts at 5 p.m. and takes place at ...
(Date:4/27/2015)... Deadly viruses such as Ebola are the target ... University City Science Center's Port business incubator at ... $4.5 million Phase 2 SBIR grant from the National ... is focused on therapies for unmet medical needs while ... first-in-class protease inhibitors based on a technology platform inspired ...
Breaking Biology Technology:ACRES Announces Innovative Clinical Research Event--SYNERGY 2ACRES Announces Innovative Clinical Research Event--SYNERGY 3ACRES Announces Innovative Clinical Research Event--SYNERGY 4iCo Therapeutics Announces Year End 2014 Financial Results 2iCo Therapeutics Announces Year End 2014 Financial Results 3iCo Therapeutics Announces Year End 2014 Financial Results 4Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 2Dr. Robert Hanzlik Discusses Pharmaceutical Testing Models at Event Hosted by National University 3New Resident of Science Center’s Port Business Incubator Targets SARS and Ebola 2
... YORK, June 15, 2011 NeoStem, Inc. ("NeoStem" or ... international biopharmaceutical company with product and service revenues, global ... business units – U.S. adult stem cells, China adult ... Kolbert, Vice President of Strategic Business Development, will present ...
... Vermillion, Inc. (NASDAQ: VRML ), a molecular ... Microcap Index when Russell Investments reconstitutes its family of U.S. ... additions posted on June 10, available at www.russell.com/indexes . ... in place for one year, means automatic inclusion in the ...
... June 15, 2011 , Pharma IQ is ... HTA Online event - ,Global HTA and CER Forum ... over the course of August. Health Technology Assessment ... assessed for pharmaceuticals in Australia, Canada,and the UK, while clinical ...
Cached Biology Technology:NeoStem to Present at Two Investor Events This Month 2NeoStem to Present at Two Investor Events This Month 3NeoStem to Present at Two Investor Events This Month 4Vermillion Announces Joining Russell Microcap® Index 2Vermillion Announces Joining Russell Microcap® Index 3Health Technology Assessment Goes Online 2Health Technology Assessment Goes Online 3
(Date:4/13/2015)... According to a recently ... & Opportunities, 2020", the global biometrics market is ... till 2020. The biometrics market is garnering attention ... review of biometric management systems. The constant development ... greater efficiency, are resulting in increasing installation of ...
(Date:4/6/2015)... Apr. 6, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... patent 62/143028 for MINIATURE, MULTI-PURPOSE ANTENNA ... NXT-ID introduces a new revolutionary method ... surrounds the use of miniature antenna modules for ...
(Date:4/1/2015)... , Apr. 1, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... smart wallets is underway to early access pre-order customers. ... includes usage at retail outlets including Walmart, Target, AT&T, ... report Wocket was accepted at all outlets and very ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 2NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 3NXT-ID Patents Miniature, Low Power Wireless Magnetic Stripe 4NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Just as inhaling cigarette smoke can cause lung cancer, inhaling ... College of Medicine of Yeshiva University have received a ... to clinically develop an inhaled therapy for lung cancer ... The grant recipients are Roman Perez-Soler, M.D., professor of ...
... Institute for Brain Science has released the world,s ... a previously unthinkable feat made possible through leading-edge ... studies and documentation. The unprecedented mappings are the ... online public resource developed to advance the Institute,s ...
... biological material available to identify persons or find next of ... cases, the kits usually employed to carry out DNA identifications ... DNA is not available, and that which is available is ... identifying persons from these small fragments of DNA. His thesis, ...
Cached Biology News:NIH funds investigation of inhaled lung cancer treatment 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 2Allen Institute for Brain Science announces first comprehensive gene map of the human brain 3Developing a tool for identification -- even using very degraded DNA samples 2Developing a tool for identification -- even using very degraded DNA samples 3
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Alpha-2-antiplasmin precursor (Alpha-2-plasmin inhibitor) (Alpha-2-PI) (Alpha-2-AP). [Source:Uniprot/SWISSPROT;Acc:P08697] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
... [HDAC8-48] to HDAC8 Regulation of ... mechanisms such as DNA methylation, ATP-dependent ... of histones, which include the dynamic ... of lysine residues present in the ...
Mouse monoclonal antibody raised against a partial recombinant AAAS. NCBI Entrez Gene ID = AAAS...
Biology Products: